PEPG
PepGen Inc.5.52
+0.05+0.91%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
379.49MP/E (TTM)
-Basic EPS (TTM)
-2.82Dividend Yield
0%Recent Filings
8-K
8-K
8-K
PepGen completes DM1 trial dosing
PepGen Inc. completed dosing in the 15 mg/kg cohort of its Phase 1 FREEDOM-DM1 trial for PGN-EDODM1, opting to end escalation after strong splicing correction at lower doses while redirecting resources to the Phase 2 FREEDOM2 multiple-dose study. Topline data from the high-dose cohort arrives early Q4 2025, with initial FREEDOM2 results in Q1 2026. Cash stands at $74.7 million, funding operations into Q2 2026. Clinical delays could hinder progress.
10-Q
Q2 FY2025 results
PepGen narrowed its R&D burn in Q2 FY2025, posting an operating loss of $23.9M, down 21% y/y from $30.4M, as it wound down its DMD program after PGN-EDO51 failed to hit dystrophin targets in the CONNECT1 trial. While six-month net loss widened to $53.3M from $46.4M y/y, driven by higher clinical costs for PGN-EDODM1, the DM1 candidate showed promising dose-dependent splicing correction up to 29.1% in the Phase 1 FREEDOM study, with 15 mg/kg data due Q4 2025. Cash and equivalents fell to $35.1M from $49.4M at year-end, with $74.7M total liquidity funding operations into Q2 2026; no debt. No free cash flow disclosed in the 10-Q. Litigation over PGN-EDO51 disclosures poses a distraction.
8-K
Annual meeting results
PepGen Inc. held its 2025 Annual Meeting on June 4, with strong stockholder turnout of 29.4 million shares. Shareholders elected Mitchell H. Finer, Heidi Henson, and Laurie B. Keating as Class III directors, despite some withheld votes for Keating. They also ratified KPMG LLP as auditors for the year ending December 31, 2025. Governance stays steady.
DSGN
Design Therapeutics, Inc.
9.62+0.50
DYN
Dyne Therapeutics, Inc.
19.55-0.04
ENGN
enGene Holdings Inc.
8.38-0.05
ETNB
89bio, Inc.
14.84+0.00
EWTX
Edgewise Therapeutics, Inc.
22.77-1.17
NGNE
Neurogene Inc.
19.53-0.73
PBM
Psyence Biomedical Ltd.
1.53+0.05
PRME
Prime Medicine, Inc.
3.88-0.16
RCKT
Rocket Pharmaceuticals, Inc.
3.43+0.02
RGNX
REGENXBIO Inc.
14.11+0.28